Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morris, D. M.
Right arrow Articles by Key, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morris, D. M.
Right arrow Articles by Key, C.

Annals of Surgical Oncology, Vol 5, Issue 4 329-337, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Localized well-differentiated thyroid carcinoma: survival analysis of prognostic factors and (131)I therapy

D. M. Morris, P. J. Boyle, C. A. Stidley, K. K. Altobelli, T. Parnell and C. Key
The University of New Mexico Cancer Research and Treatment Center, Department of Surgery, The University of New Mexico School of Medicine, Albuquerque 87131-5341, USA.

BACKGROUND: Recommendations regarding therapeutic use of (131)I for patients with well-differentiated thyroid cancer remain controversial. Between 1969 and 1993, 1171 patients with papillary (including mixed) or follicular thyroid cancer were reported to the New Mexico Tumor Registry. Of these, 1075 cases (77.6% female, median age 41 years) were available for analysis of survival plots and previously recognized risk factors. Extent of operation was documented for 344 patients. METHODS: One hundred twenty-seven (37%) patients underwent postoperative (131)I ablation. Median follow-up was 99 months. A proportional hazards model was constructed using age, gender, stage, histology, and use of radioiodine. The same variables plus extent of operation were examined in the smaller group. RESULTS: Kaplan-Meier survival estimates at 12 years were 96.2% for patients younger than 45 years and 68.6% for those older than 45 years. Age, gender, and histology, but not stage, were important survival variables (P <.05). Adjusting for other risk factors, there was no apparent survival benefit associated with radioiodine following clinically appropriate thyroidectomy. Findings from the small group mirrored those of the large group. CONCLUSIONS: (131)I may not be as efficacious as previously believed for patients with well-differentiated thyroid cancer confined to the neck.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
A. M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, and H. C. Gerstein
A Systematic Review and Metaanalysis of the Effectiveness of Radioactive Iodine Remnant Ablation for Well-Differentiated Thyroid Cancer
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3668 - 3676.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
M. E. Spieth, S. B. Standiford, M. E. Starkman, and J. Gough
Recombinant TSH-Stimulated, Radioguided Differentiated Thyroid Carcinoma Surgery
Clin. Med. Res., January 1, 2003; 1(1): 53 - 56.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the Society of Surgical Oncology.